Predictive value of circulating cystatin C level in patients with acute coronary syndrome: a meta-analysis

References

• Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333–1341.
   PubMed Web of Science ®Google Scholar
• Chacko S, Haseeb S, Glover BM, et al. The role of biomarkers in the diagnosis and risk stratification of acute coronary syndrome. Future Sci Oa. 2018;4(1):FSO251.
   PubMed Web of Science ®Google Scholar
• Shuvy M, Chen S, Vorobeichik D, et al. Temporal trends in management and outcomes of patients with acute coronary syndrome according to renal function. Int J Cardiol. 2017;232:48–52.
   PubMed Web of Science ®Google Scholar
• Pickering JW, Blunt IRH, Than MP. Acute kidney injury and mortality prognosis in acute coronary syndrome patients: a meta-analysis. Nephrology (Carlton). 2018;23(3):237–246.
   PubMed Web of Science ®Google Scholar
• Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 2004;41(5–6):467–550.
   PubMed Web of Science ®Google Scholar
• Shimizu-Tokiwa A, Kobata M, Io H, et al. Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron. 2002;92(1):224–226.
   PubMed Web of Science ®Google Scholar
• Jernberg T, Lindahl B, James S, et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110(16):2342–2348.
   PubMed Web of Science ®Google Scholar
• Ichimoto E, Jo K, Kobayashi Y, et al. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J. 2009;73(9):1669–1673.
   PubMed Web of Science ®Google Scholar
• Garcia Acuna JM, Gonzalez-Babarro E, Grigorian Shamagian L, et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol. 2009;62:510–519.
   PubMed Web of Science ®Google Scholar
• Taglieri N, Fernandez-Berges DJ, Koenig W, et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis. 2010;209(1):300–305.
   PubMed Web of Science ®Google Scholar
• Manzano-Fernandez S, Lopez-Cuenca A, Januzzi JL, et al. Usefulness of beta-trace protein and cystatin C for the prediction of mortality in non ST segment elevation acute coronary syndromes. Am J Cardiol. 2012;110(9):1240–1248.
   PubMed Web of Science ®Google Scholar
• Sun TW, Xu QY, Yao HM, et al. The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. Heart Lung. 2012;41(5):456–462.
   PubMed Web of Science ®Google Scholar
• Silva D, Cortez-Dias N, Jorge C, et al. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol. 2012;109(10):1431–1438.
   PubMed Web of Science ®Google Scholar
• Fouad M, Boraie M. Cystatin C as an early marker of acute kidney injury and predictor of mortality in the intensive care unit after acute myocardial infarction. Arab J Nephrol Transplant. 2013;6(1):21–26.
   PubMedGoogle Scholar
• Akgul O, Uyarel H, Ergelen M, et al. Predictive value of elevated cystatin C in patients undergoing primary angioplasty for ST-elevation myocardial infarction. J Crit Care. 2013;28:882 e813.
   PubMed Web of Science ®Google Scholar
• Yang S, Song L, Zhao L, et al. Predictive value of cystatin C in people with suspected or established coronary artery disease: a meta-analysis. Atherosclerosis. 2017;263:60–67.
   PubMed Web of Science ®Google Scholar
• Einwoegerer CF, Domingueti CP. Association between increased levels of cystatin C and the development of cardiovascular events or mortality: a systematic review and meta-analysis. Arq Bras Cardiol. 2018;111:796–807.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W264.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. [accessed March 16 2020]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Shen G, Zhu H, Ding H, et al. Increased cystatin C level in ST-elevation myocardial infarction predisposes the prognosis of angioplasty. Am J Cardiol. 2018;355(6):530–536.
   Google Scholar
• Yan S, Zhang X, Tian X, et al. The predictive value of plasma cystatin C for non-ST-elevation acute coronary syndrome treated with percutaneous coronary intervention. Zhonghua Xue Zhi. 2014;94:10–13.
   PubMedGoogle Scholar
• Fu Z, Yang X, Shen M, et al. Prognostic ability of cystatin C and homocysteine plasma levels for long-term outcomes in very old acute myocardial infarction patients. Clin Interv Aging. 2018;13:1201–1209.
   PubMed Web of Science ®Google Scholar
• Chen Y, Fan Y, Men M, et al. High cystatin C levels predict long-term mortality in patients with ST-segment elevation myocardial infarction undergoing late percutaneous coronary intervention: A retrospective study. Clin Cardiol. 2019;42(5):572–578.
   PubMed Web of Science ®Google Scholar
• Mao Q, Zhao N, Wang Y, et al. Association of cystatin C with metabolic syndrome and its prognostic performance in non-ST-segment elevation acute coronary syndrome with preserved renal function. Biomed Res Int. 2019;2019:1–11.
   Web of Science ®Google Scholar
• Barbarash OL, Bykova IS, Kashtalap VV, et al. Serum neutrophil gelatinase-associated lipocalin has an advantage over serum cystatin C and glomerular filtration rate in prediction of adverse cardiovascular outcome in patients with ST-segment elevation myocardial infarction. BMC Cardiovasc Disord. 2017;17(1):81.
   PubMedGoogle Scholar
• Ristiniemi N, Lund J, Tertti R, et al. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem. 2012;45(7–8):535–540.
   PubMed Web of Science ®Google Scholar
• Kilic T, Oner G, Ural E, et al. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis. 2009;207(2):552–558.
   PubMed Web of Science ®Google Scholar
• Akerblom A, Wallentin L, Siegbahn A, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clin Chem. 2012;58(1):190–199.
   PubMed Web of Science ®Google Scholar
• Lindholm D, James SK, Gabrysch K, et al. Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study. JAMA Cardiol. 2018;3(12):1160–1166.
   PubMed Web of Science ®Google Scholar
• Windhausen F, Hirsch A, Fischer J, et al. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem. 2009;55(6):1118–1125.
   PubMed Web of Science ®Google Scholar
• Rozenbaum Z, Benchetrit S, Minha S, et al. The effect of admission renal function on the treatment and outcome of patients with acute coronary syndrome. Cardiorenal Med. 2017;7(3):169–178.
   PubMed Web of Science ®Google Scholar
• Chua SK, Lo HM, Chiu CZ, et al. Prognostic impact of renal dysfunction in patients with acute coronary syndrome-role beyond the CHA2 DS2 -VASc score: data from Taiwan acute coronary syndrome full spectrum registry. Nephrology. 2016;21(7):583–591.
   PubMed Web of Science ®Google Scholar
• Mafham M, Emberson J, Landray MJ, et al. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS One. 2011;6(10):e25920.
   PubMed Web of Science ®Google Scholar
• Filler G, Bokenkamp A, Hofmann W, et al. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem. 2005;38(1):1–8.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lu B, Sheng X, et al. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis. 2011;58(3):356–365.
   PubMed Web of Science ®Google Scholar
• Zhou H, Yang M, He X, et al. eGFR, cystatin C and creatinine in shrunken pore syndrome. Clin Chim Acta. 2019;498:1–5.
   PubMed Web of Science ®Google Scholar
• Grubb A. Shrunken pore syndrome – a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options. Clin Biochem. 2020;83:12–20.
   PubMed Web of Science ®Google Scholar
• Herou E, Dardashti A, Nozohoor S, et al. The mortality increase in cardiac surgery patients associated with shrunken pore syndrome correlates with the eGFRcystatin C/eGFRcreatinine-ratio. Scand J Clin Lab Invest. 2019;79(3):167–173.
   PubMed Web of Science ®Google Scholar
• Dardashti A, Nozohoor S, Grubb A, et al. Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting. Scand J Clin Lab Invest. 2016;76(1):74–81.
   PubMed Web of Science ®Google Scholar
• Akesson A, Lindstrom V, Nyman U, et al. Shrunken pore syndrome and mortality: a cohort study of patients with measured GFR and known comorbidities. Scand J Clin Lab Invest. 2020;80:412–422.
   PubMed Web of Science ®Google Scholar
• Purde MT, Nock S, Risch L, et al. The cystatin C/creatinine ratio, a marker of glomerular filtration quality: associated factors, reference intervals, and prediction of morbidity and mortality in healthy seniors. Transl Res. 2016;169:80–90. e81–82.
   PubMed Web of Science ®Google Scholar
• Almen MS, Bjork J, Nyman U, et al. Shrunken pore syndrome is associated with increased levels of atherosclerosis-promoting proteins. Kidney Int Rep. 2019;4(1):67–79.
   PubMed Web of Science ®Google Scholar
• Salgado JV, Souza FL, Salgado BJ. How to understand the association between cystatin C levels and cardiovascular disease: imbalance, counterbalance, or consequence? J Cardiol. 2013;62(6):331–335.
   PubMed Web of Science ®Google Scholar
• Antoniadis AP, Chatzizisis YS, Giannoglou GD. Pathogenetic mechanisms of coronary ectasia. Int J Cardiol. 2008;130(3):335–343.
   PubMed Web of Science ®Google Scholar
• Zhai JL, Ge N, Zhen Y, et al. Corticosteroids significantly increase serum cystatin C concentration without affecting renal function in symptomatic heart failure. Clin Lab. 2016;62:203–207.
   PubMed Web of Science ®Google Scholar
• Al Musaimi O, Abu-Nawwas AH, Al Shaer D, et al. Influence of age, gender, smoking, diabetes, thyroid and cardiac dysfunctions on cystatin C biomarker. Semergen. 2019;45(1):44–51.
   PubMedGoogle Scholar